- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
- EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
- EQS-News: Evotec reports Q1 2024 results and provides corporate update
- EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2023 pursuant Evotec’s remuneration system.
- EQS-News: Bayer and Evotec collaborate to advance precision cardiology
- EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
- EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
- EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
More ▼
Key statistics
On Wednesday, Evotec SE (EVT:BRN) closed at 8.45, 0.00% above its 52-week low of 8.45, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.78 |
---|---|
High | 8.78 |
Low | 8.45 |
Bid | 8.39 |
Offer | 8.43 |
Previous close | 8.45 |
Average volume | 566.50 |
---|---|
Shares outstanding | 177.54m |
Free float | 161.18m |
P/E (TTM) | -- |
Market cap | 1.77bn EUR |
EPS (TTM) | -0.4743 EUR |
Data delayed at least 15 minutes, as of May 29 2024.
More ▼